The controversial 2013 revision of the cholesterol guidelines means nearly half of the United States population between the ages of forty and seventy-five can now be labeled “high risk.”303 And drug companies are raking it in. According to Harvard’s Dr. John Abramson and former New England Journal of Medicine editor Dr. Jerome Kassirer, the reason our medical leadership plays along, unflinchingly insisting that there’s no potential harm from pushing these numbers so low, may stem from financial conflicts of interest.
